8-K 1 d272923d8k.htm 8-K 8-K





Washington, D.C. 20549







Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 18, 2022



Vertex Pharmaceuticals Incorporated

(Exact name of registrant as specified in its charter)




Massachusetts   000-19319   04-3039129

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)

50 Northern Avenue

Boston, Massachusetts 02210

(Address of principal executive offices) (Zip Code)

(617) 341-6100

(Registrant’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, $0.01 Par Value Per Share   VRTX   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 5.07 Submission of Matters to a Vote of Security Holders

The annual meeting of shareholders of Vertex Pharmaceuticals Incorporated (the “Company”) was held on May 18, 2022 (the “Annual Meeting”). Set forth below are the voting results for each of the proposals submitted to a vote of the Company’s shareholders at the Annual Meeting:

Proposal No. 1: Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Terrence Kearney, Reshma Kewalramani, Yuchun Lee, Jeffrey Leiden, Margaret McGlynn, Diana McKenzie, Bruce Sachs and Suketu “Suky” Upadhyay to serve as members of the Company’s board of directors until the annual meeting of shareholders to be held in 2023:


     For      Against      Abstain      Non-Votes  

Sangeeta Bhatia

     217,866,026        1,537,431        580,314        9,807,714  

Lloyd Carney

     190,655,522        29,245,505        82,744        9,807,714  

Alan Garber

     215,431,689        4,470,485        81,597        9,807,714  

Terrence Kearney

     197,133,280        22,764,797        85,694        9,807,714  

Reshma Kewalramani

     218,747,353        1,157,114        79,304        9,807,714  

Yuchun Lee

     215,091,147        4,791,160        101,464        9,807,714  

Jeffrey Leiden

     212,867,068        7,033,947        82,756        9,807,714  

Margaret McGlynn

     214,622,981        4,782,385        578,405        9,807,714  

Diana McKenzie

     217,787,588        1,616,738        579,445        9,807,714  

Bruce Sachs

     207,274,411        11,876,210        833,150        9,807,714  

Suketu “Suky” Upadhyay

     219,273,791        610,013        99,967        9,807,714  

Proposal No. 2: Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022:


     For      Against      Abstain      Non-Votes  
     177,775,597        51,927,015        88,873        0  

Proposal No. 3: Based upon the following votes, the shareholders approved, on an advisory basis, the 2021 compensation program for the Company’s named executive officers:


     For      Against      Abstain      Non-Votes  
     202,178,849        16,105,504        1,699,418        9,807,714  

Proposal No. 4: Based up the following votes, the shareholders approved the amendment and restatement of the Company’s 2013 Stock and Option Plan to increase the number of shares authorized for issuance under this plan by 13.5 million shares.


     For      Against      Abstain      Non-Votes  
     194,088,034        25,773,390        122,347        9,807,714  


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: May 18, 2022






/s/ Joy Liu


Joy Liu


Senior Vice President, General Counsel